{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:06:42Z","timestamp":1792796802303,"version":"4.5.0"},"reference-count":49,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union\u2014NextGenerationEU","award":["BG-RRP-2.004-0004-C01"],"award-info":[{"award-number":["BG-RRP-2.004-0004-C01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Natural alkaloid galantamine is widely used for the treatment of mild to moderate Alzheimer\u2019s dementia. Galantamine hydrobromide (GH) is available as fast-release tablets, extended-release capsules, and oral solutions. However, its oral delivery can cause some unwanted side effects, such as gastrointestinal disturbances, nausea, and vomiting. Intranasal administration is one possible way to avoid such unwanted effects. In this work, chitosan-based nanoparticles (NPs) were studied as potential GH delivery vehicles for nasal application. The NPs were synthesized via ionic gelation and studied using dynamic light scattering (DLS) as well as by spectroscopic and thermal methods. The GH-loaded chitosan\u2013alginate complex particles were also prepared as a way to modify the release of GH. The high loading efficiency of the GH was confirmed for both types of particles, at 67% for the GH-loaded chitosan NPs and 70% for the complex chitosan\/alginate GH-loaded particles. The mean particle size of the GH-loaded chitosan NPs was about 240 nm, while the sodium alginate coated chitosan particles loaded with GH were expectedly bigger, with a mean particle size of ~286 nm. GH release profiles in PBS at 37 \u00b0C were obtained for both types of NPs, and it was found that the GH-loaded chitosan NPs allowed the prolonged release of the incorporated drug for a period of 8 h, while the complex GH-loaded chitosan\/alginate NPs released the incorporated GH faster. The stability of the prepared GH-loaded NPs was also demonstrated after 1 year of storage at 5 \u00b0C \u00b1 3 \u00b0C.<\/jats:p>","DOI":"10.3390\/pharmaceutics15030829","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T02:56:50Z","timestamp":1677812210000},"page":"829","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Chitosan-Based Nanoparticles for Targeted Nasal Galantamine Delivery as a Promising Tool in Alzheimer\u2019s Disease Therapy"],"prefix":"10.3390","volume":"15","author":[{"given":"Dilyana","family":"Georgieva","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Technology and Biopharmacy, Faculty of Pharmacy, Medical University of Sofia, 2 Dunav Str., 1000 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denitsa","family":"Nikolova","sequence":"additional","affiliation":[{"name":"Laboratory on Structure and Properties of Polymers, Faculty of Chemistry and Pharmacy, University of Sofia, 1 James Bourchier Blvd., 1164 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0566-5883","authenticated-orcid":false,"given":"Elena","family":"Vassileva","sequence":"additional","affiliation":[{"name":"Laboratory on Structure and Properties of Polymers, Faculty of Chemistry and Pharmacy, University of Sofia, 1 James Bourchier Blvd., 1164 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bistra","family":"Kostova","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology and Biopharmacy, Faculty of Pharmacy, Medical University of Sofia, 2 Dunav Str., 1000 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/archfami.8.4.347","article-title":"Alzheimer disease: Report of the council on scientific affairs","volume":"8","author":"Guttman","year":"1999","journal-title":"Arch. Fam. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1517\/14656566.2011.520702","article-title":"Current perspectives on pharmacotherapy of Alzheimer\u2019s disease","volume":"12","author":"Chopra","year":"2011","journal-title":"Expert Opin. Pharm."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2165\/00003495-200060050-00008","article-title":"Galantamine: A review of its use in Alzheimer\u2019s disease","volume":"60","author":"Scott","year":"2000","journal-title":"Drugs"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.brainresbull.2011.03.010","article-title":"Galantamine potentiates the protective effect of rofecoxib and caffeic acid against intrahippocampal Kainic acid-induced cognitive dysfunction in rat","volume":"85","author":"Kumar","year":"2011","journal-title":"Brain Res. Bull."},{"key":"ref_5","first-page":"420","article-title":"Pharmacokinetics of galantamine in humans and corresponding cholinesterase inhibition","volume":"50","author":"Bickel","year":"1991","journal-title":"Clin. Pharm."},{"key":"ref_6","first-page":"45","article-title":"The tolerability and safety of cholinesterase inhibitors in the treatment of dementia","volume":"127","author":"Inglis","year":"2002","journal-title":"Int. J. Clin. Prac. Suppl."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","article-title":"Intranasal delivery of biologics to the central nervous system","volume":"64","author":"Lochhead","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3109\/10717544.2014.880860","article-title":"Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington\u2019s disease","volume":"22","author":"Bhatt","year":"2015","journal-title":"Drug Deliv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3109\/10717544.2013.860501","article-title":"Nasal in-situ gels for delivery of rasagiline mesylate: Improvement in bioavailability and brain localization","volume":"22","author":"Ravi","year":"2015","journal-title":"Drug Deliv."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejpb.2015.03.024","article-title":"Development of a novel adjuvanted nasal vaccine: C48\/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity","volume":"93","author":"Bento","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"592238","DOI":"10.3389\/fphar.2020.592238","article-title":"Nasal Delivery of Hesperidin\/Chitosan Nanoparticles Suppresses Cytokine Storm Syndrome in a Mouse Model of Acute Lung Injury","volume":"11","author":"Jin","year":"2021","journal-title":"Front. Pharm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ajps.2017.09.001","article-title":"Intranasal administration of carbamazepine-loaded carboxymethyl chitosan nanoparticles for drug delivery to the brain","volume":"13","author":"Liu","year":"2018","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1023\/A:1018908705446","article-title":"Enhancement of Nasal Absorption of Insulin Using Chitosan Nanoparticles","volume":"16","author":"Calvo","year":"1999","journal-title":"Pharm. Res."},{"key":"ref_14","first-page":"51","article-title":"Nose to Brain Delivery of Galantamine Loaded Nanoparticles: In-vivo Pharmacodynamic and Biochemical Study in Mice","volume":"16","author":"Singh","year":"2019","journal-title":"Curr. Drug Deliv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.3109\/10717544.2016.1153748","article-title":"Pharmacological, toxicological and neuronal localization assessment of galantamine\/chitosan complex nanoparticles in rats: Future potential contribution in Alzheimer\u2019s disease management","volume":"23","author":"Hanafy","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1007\/s00216-021-03487-1","article-title":"LC-MS bioanalysis of targeted nasal galantamine bound chitosan nanoparticles in rats\u2019 brain homogenate and plasma","volume":"413","author":"Agami","year":"2021","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/03639045.2021.1934861","article-title":"Intranasal galantamine\/chitosan complex nanoparticles elicit neuroprotection potentials in rat brains via antioxidant effect","volume":"47","author":"Kandil","year":"2021","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_18","unstructured":"Belgacem, M.N., and Gandini, A. (2008). Monomers, Polymers and Composites from Renewable Resources, Elsevier."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/cben.201400025","article-title":"A review on chitin and chitosan polymers: Structure, chemistry, solubility, derivatives, and applications","volume":"2","author":"Zargar","year":"2015","journal-title":"ChemBioEng Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.22271\/phyto.2018.v7.isp6.1.01","article-title":"A review on chitosan nanoparticles applications in drug delivery","volume":"7","author":"Roy","year":"2018","journal-title":"J. Pharm. Phytochem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1099\/jmm.0.000445","article-title":"Biocompatible biodegradable polymeric antibacterial nanoparticles for enhancing the effects of a third-generation cephalosporin against resistant bacteria","volume":"66","author":"Mushtaq","year":"2017","journal-title":"J. Med. Microbiol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Karava, A., Lazaridou, M., Nanaki, S., Michailidou, G., Christodoulou, E., Kostoglou, M., Iatrou, H., and Bikiaris, D.N. (2020). Chitosan Derivatives with Mucoadhesive and Antimicrobial Properties for Simultaneous Nanoencapsulation and Extended Ocular Release Formulations of Dexamethasone and Chloramphenicol Drugs. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12060594"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Mohammed, M.A., Syeda, J.T.M., Wasan, K.M., and Wasan, E.K. (2017). An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery. Pharmaceutics, 9.","DOI":"10.3390\/pharmaceutics9040053"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.proeng.2017.07.034","article-title":"Biopolymers in medical implants: A brief review","volume":"200","author":"Rebelo","year":"2017","journal-title":"Procedia Eng."},{"key":"ref_25","first-page":"670","article-title":"Chitosan physical forms: A short review","volume":"5","author":"Nasef","year":"2011","journal-title":"Aust. J. Basic Appl. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ijbiomac.2014.08.052","article-title":"Chitosan as a suitable nanocarrier material for anti-Alzheimer drug delivery","volume":"72","author":"Sarvaiya","year":"2015","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ouyang, Q.Q., Zhao, S., Li, S.D., and Song, C. (2017). Application of chitosan, chitooligosaccharide, and their derivatives in the treatment of Alzheimer\u2019s disease. Mar. Drugs, 15.","DOI":"10.3390\/md15110322"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Manek, E., Darvas, F., and Petroianu, G.A. (2020). Use of biodegradable, chitosan-based nanoparticles in the treatment of Alzheimer\u2019s disease. Molecules, 25.","DOI":"10.3390\/molecules25204866"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Jhaveri, J., Raichura, Z., Khan, T., Momin, M., and Omri, A. (2021). Chitosan Nanoparticles-Insight into Properties, Functionalization and Applications in Drug Delivery and Theranostics. Molecules, 26.","DOI":"10.3390\/molecules26020272"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0168-3659(95)00129-8","article-title":"Preparation and characterization of chitosan microsphere as drug carrier for prednisolone sodium phosphate as model for anti-inflammatory drugs","volume":"39","author":"Berthold","year":"1996","journal-title":"J. Control. Release"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6017","DOI":"10.1021\/cr030441b","article-title":"Chitosan Chemistry and Pharmaceutical Perspectives","volume":"104","author":"Kumar","year":"2004","journal-title":"Chem. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3389\/fbioe.2020.00389","article-title":"Potential of Chitosan and Its Derivatives for Biomedical Applications in the Central Nervous System","volume":"8","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.3390\/md8041305","article-title":"Chitosan based polyelectrolyte complexes as potential carrier materials in drug delivery systems","volume":"8","author":"Hamman","year":"2010","journal-title":"Mar. Drugs"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1179\/174328408X341744","article-title":"Chitosan composites for biomedical applications: Status, challenges and perspectives","volume":"24","author":"Hein","year":"2008","journal-title":"Mater. Sci. Technol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1023\/A:1012128907225","article-title":"Chitosan and chitosan\/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines","volume":"14","author":"Calvo","year":"1997","journal-title":"Pharm. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1021\/mp300162j","article-title":"Insight on the Formation of Chitosan Nanoparticles through Ionotropic Gelation with Tripolyphosphate","volume":"9","author":"Koukaras","year":"2012","journal-title":"Mol. Pharm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.carbpol.2009.02.019","article-title":"Evaluation of Alginate\/Chitosan nanoparticles as antisense delivery vector: Formulation, optimization and in vitro characterization","volume":"77","author":"Gazori","year":"2009","journal-title":"Carbohydr. Polym."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S2222-1808(14)60590-9","article-title":"Comparison of chitosan, alginate and chitosan\/alginate nanoparticles with respect to their size, stability, toxicity and transfection","volume":"4","author":"Rafiee","year":"2014","journal-title":"Asian Pac. J. Trop. Dis."},{"key":"ref_39","first-page":"513","article-title":"Chitosan\u2013sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: Formulation, optimization and in vitro characterization","volume":"68","author":"Motwani","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.3109\/03639045.2015.1062897","article-title":"Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer\u2019s disease management: Preparation and detection in rat brain","volume":"41","author":"Hanafy","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_41","first-page":"16","article-title":"Determination of water content and dynamic vapor sorption using gravimetric methods, Karl Fischer titration and thermal analysis","volume":"48","author":"Wagner","year":"2016","journal-title":"Am. Lab."},{"key":"ref_42","unstructured":"O\u2019Neil, M.J. (2006). The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals, Merck Inc.. [14th ed.]."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jddst.2018.10.020","article-title":"Potential of Chitosan and its derivatives for controlled drug release applications\u2013A review","volume":"49","author":"Safdar","year":"2019","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Aranaz, I., Alc\u00e1ntara, A.R., Civera, M.C., Arias, C., Elorza, B., Heras Caballero, A., and Acosta, N. (2021). Chitosan: An Overview of Its Properties and Applications. Polymer, 13.","DOI":"10.3390\/polym13193256"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e08674","DOI":"10.1016\/j.heliyon.2021.e08674","article-title":"Drug release study of the chitosan-based nanoparticles","volume":"8","author":"Herdiana","year":"2022","journal-title":"Heliyon"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"146320","DOI":"10.1155\/2013\/146320","article-title":"Development of Chitosan Nanoparticles as a Stable Drug Delivery System for Protein\/siRNA","volume":"2013","author":"Katas","year":"2013","journal-title":"Int. J. Biomater."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.3390\/md13041819","article-title":"Stability of chitosan\u2014A challenge for pharmaceutical and biomedical applications","volume":"13","author":"Winnicka","year":"2015","journal-title":"Mar. Drugs"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3109\/03639045.2013.782501","article-title":"Effect of moisture content, temperature and exposure time on the physical stability of chitosan powder and tablets","volume":"40","author":"Viljowen","year":"2014","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.addr.2005.07.001","article-title":"The basics and underlying mechanisms of mucoadhesion","volume":"57","author":"Smart","year":"2005","journal-title":"Adv. Drug Deliv. Rev."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/3\/829\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:46:52Z","timestamp":1760122012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/3\/829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":49,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["pharmaceutics15030829"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15030829","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,3]]}}}